Modality
Fusion Protein
MOA
HPK1i
Target
PD-L1
Pathway
DDR
TTR Amyloidosis
Development Pipeline
Preclinical
~Jun 2019
→ ~Sep 2020
Phase 1
~Dec 2020
→ ~Mar 2022
Phase 2
~Jun 2022
→ ~Sep 2023
Phase 3
Dec 2023
→ May 2028
Phase 3Current
NCT03778407
797 pts·TTR Amyloidosis
2023-12→2028-05·Active
NCT07561331
2,013 pts·TTR Amyloidosis
2024-06→2026-10·Not yet recruiting
2,810 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-10-217mo awayPh3 Readout· TTR Amyloidosis
2028-05-212.1y awayPh3 Readout· TTR Amyloidosis
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P3
Active
P3
Not yet…
Catalysts
Ph3 Readout
2026-10-21 · 7mo away
TTR Amyloidosis
Ph3 Readout
2028-05-21 · 2.1y away
TTR Amyloidosis
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03778407 | Phase 3 | TTR Amyloidosis | Active | 797 | LiverFat |
| NCT07561331 | Phase 3 | TTR Amyloidosis | Not yet recr... | 2013 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 | |
| Polatuximab | Nuvalent | Approved | PD-L1 | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | PD-L1 | |
| Voxaderotide | Viking Therapeutics | Approved | PD-L1 |